Zacks Investment Research upgraded shares of FLAMEL TECH (FLML) from UNDERPERFORM to NEUTRAL on July 10, 2012, with a target price of $5.60.
Flamel Technologies S.A. is principally engaged in the development of advanced polymer technologies for unique medicinal applications. To meet important medical needs and develop commercially valuable products, they are building on their primary technology platforms: the Medusa system for the controlled peritoneal delivery of proteins and peptides, and the Micropump system for the controlled delivery of certain oral drugs. (press release)
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on FLAMEL TECH (FLML),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment